# Novo Nordisk Shares Jump After Strong Q3 Results

> Novo Nordisk's stock surged 6% post-earnings as oral Wegovy drives recovery.
- Title: Novo Nordisk Shares Jump After Strong Q3 Results | Shortify
- Summary: Novo Nordisk's stock surged 6% post-earnings as oral Wegovy drives recovery. Novo Nordisk raised 2026 fiscal year guidance after strong Q3 results with oral…
- Keywords: novo nordisk, wegovy, oral weight loss pill, q3 results, stock price, financial guidance, diabetes medicine, weight loss market, The Motley Fool
- Source: The Motley Fool — https://fool.com/investing/2026/11/07/novo-nordisk-just-delivered-great-news-for-investors-is-a-comeback-finally-underway
- Author: Prosper Junior Bakiny
- Published: 2026-11-07T23:20:02+00:00
- Read time: 1 min
- Topics: novo nordisk, wegovy, oral weight loss pill, q3 results, stock price, financial guidance, diabetes medicine, weight loss market, finance, money
## Novo Nordisk Q3 Results
Novo Nordisk reported strong third-quarter results with oral Wegovy generating 5.4 billion dkk revenue.

> The company launched this weight loss pill, the first of its kind to earn approval, in January
## Oral Wegovy Performance
Oral Wegovy has surpassed three million prescriptions with 80% of patients new to GLP-1 treatments.

> as of June, oral wegovy had surpassed three million prescriptions, and more than 80% were for patients who had never taken glp-1s before
## Q3 Financials
Novo's net sales rose 6% year over year to 79.2 billion dkk despite 16% net income drop.

> Novo reported that, as of June, oral wegovy had surpassed three million prescriptions
## Guidance Update
Novo raised 2026 fiscal year guidance with revenue expected flat year over year versus previous 3% drop forecast.

> It now expects revenue to be flat (at the midpoint) year over year, while the previous guidance implied a 3% year-over-year drop at the midpoint
## Oral Wegovy Catalysts
Oral Wegovy approved in Germany and U.K. with potential label expansion for metabolic dysfunction.

> Novo has submitted an application to the u.s. food and drug administration for oral wegovy as a potential treatment for metabolic dysfunction-associated steatohepatitis
## CagriSema Development
CagriSema shows promise in weight loss and diabetes with potential to steal market share from Eli Lilly.

> CagriSema also posted strong clinical trial results in diabetes
## Pipeline Candidates
Zenagamtide in subcutaneous and oral formulations for diabetes and weight loss.

> The company's phase 3 pipeline features zenagamtide, a promising diabetes and weight-loss medicine
## Key takeaway

Novo Nordisk raised 2026 fiscal year guidance after strong Q3 results with oral Wegovy generating $810 million revenue.